Received by email:

File: CVR Medical.News Release (March 23, 2018) (W0352863xB74B6).pdf

                       NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                              OR FOR DISSEMINATION IN THE UNITED STATES



              CVR Medical Announces Closing of
                 Final Tranche of Financing
VANCOUVER, BC / March 23, 2018 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM)
(FRANKFURT: B3BN) (OTCQB: CRRVF) ("CVR Medical") is pleased to announce that it has closed
the final tranche (the "Final Tranche") of its previously announced non-brokered private placement
financing (the "Financing").

An aggregate of 1,281,646 units ("Units") at a price of $0.40 per Unit were issued in the Final Tranche for
gross proceeds of $512,658.40.

Net proceeds from the Financing will be used by CVR Medical for ongoing working capital requirements
relating to the Joint Venture described below, specifically in regards to FDA applications and clinical trials.

Each Unit consists of one common share of CVR Medical (each, a "Share") and one-half of one transferable
common share purchase warrant (each, whole warrant, a "Warrant"). Each Warrant is exercisable at a
price of $0.70 until March 21, 2019.

In the Final Tranche closing, CVR Medical paid finder's fees of 6% cash and 6% compensation warrants
(the "Compensation Warrants") comprised of an aggregate cash commission of $28,800 and a total of
72,000 Compensation Warrants. The Compensation Warrants have substantially the same terms as the
Warrants but are not transferable.

The Shares, the Warrants and the Compensation Warrants are subject to a hold period expiring July 22,
2018. The Financing remains subject to final acceptance of the TSX Venture Exchange.

The securities referred to herein will not be or have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.

For additional information on the organization, leadership, and current news please visit the company
website at www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint
Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a
proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a
diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a
proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
(signed) Peter Bakema
Peter Bakema
CEO, President and Director

For further information contact:
                             NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                                   OR FOR DISSEMINATION IN THE UNITED STATES


Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888




This press release contains forward-looking information that involves various risks and uncertainties regarding future
---> events
related to the Joint Venture and the proposed Financing. Such statements are subject to risks and uncertainties that m
--->ay cause
actual results, performance or developments to differ materially from those contained in the statements and are not gu
--->arantees of
future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking
---> statements
will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements ref
--->lect
management's current views and are based on certain expectations, estimates and assumptions which may prove to be inco
--->rrect.
A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implie
--->d by the
forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationa
--->lly, (2)
the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of 
--->medicine,
(3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and
development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business pla
--->n, (6) inability
to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's co
--->ntrol. These
forward-looking statements are made as of the date of this news release and, except as required by law, the Company as
--->sumes no
obligation to update these forward-looking statements, or to update the reasons why actual results differed from those
---> projected
in the forward-looking statements.


THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE
CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.